Lantheus Holdings vs Royalty Pharma
Royalty Pharma is the larger business, with $2.38bn of revenue in fiscal 2025 against $1.54bn for Lantheus Holdings (1.5 times as much). Royalty Pharma grew faster (5.1% against 0.5%). Royalty Pharma kept more of each dollar of sales as profit: a net margin of 32.4% against 15.2%. Lantheus Holdings carries less debt relative to equity (52.2% against 92.1%).
| Latest fiscal year | Lantheus HoldingsLNTH, 2025 | Royalty PharmaRPRX, 2025 |
|---|---|---|
| Revenue | $1.54bn | $2.38bn |
| Revenue growth | 0.5% | 5.1% |
| Net income | $234m | $771m |
| Operating margin | 20.2% | 65.6% |
| Net margin | 15.2% | 32.4% |
| Return on equity | 21.4% | 7.7% |
| Free cash flow | $354m | — |
| Cash | $359m | $619m |
| Total debt | $569m | $8.95bn |
| Debt to equity | 52.2% | 92.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $300m | $1.23bn |
| Employees | 1,193 | 100 |
| Market value | $6.56bn | $36.94bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | 63 (Moderate) | — |
| Insider trades, 12 months | 0 buys, 5 sales | 0 buys, 74 sales |